Gregory D. Sides
Eli Lilly and Company
26 Papers
165 Citations
Gregory D. Sides is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Dirithromycin & Tadalafil. The author has an hindex of 15, co-authored 26 publications.
Chat about Author
Papers
Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T. McVary,Claus G. Roehrborn,Jed Kaminetsky,Stephen Auerbach,Barton Wachs,Jay M. Young,Anne Esler,Gregory D. Sides,Bela S. Denes +8 more
TL;DR: Tadalafil significantly improved the mean change from baseline in International Prostate Symptom Score at 6 weeks and at 12 weeks and made significant improvements in the Benign Prostatic Hyperplasia Impact Index (significant at12 weeks) vs placebo.
376
Retinal effects of 6 months of daily use of tadalafil or sildenafil.
William H. Cordell,Raj K. Maturi,Timothy M. Costigan,Michael F. Marmor,Richard G. Weleber,Stuart G Coupland,Ronald P. Danis,John W. McGettigan,Andrew N. Antoszyk,Suzanne Klise,Gregory D. Sides +10 more
TL;DR: No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tadalafil or sildenafil for 6 months, and the medications were well tolerated.
63
Pharmacokinetics of dirithromycin
TL;DR: Dirithromycin is a new member of the macrolide class of antibiotics and has been developed for oral administration and has shown less potential to interact with other drugs metabolized by the cytochrome P450 system that does erythromycin.
47
QT Interval Prolongation as a Biomarker for Torsades de Pointes and Sudden Death in Drug Development
TL;DR: The basis for the use of the QT interval as a biomarker will be examined and drugs that increase heart rate show an apparent increase in QT intervals that confounds assessment of a true drug effect on cardiac ventricular repolarization.
Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis.
TL;DR: In this paper, dirithromycin, a new macrolide, was compared with penicillin for the treatment of streptococcal pharyngitis for patients 12 years of age and older.
21